Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 102-108

  Bock, Allison M ^a   Cao, Qing ^b   Ferrieri, Patricia ^a   Young, Jo Anne H ^a   Weisdorf, Daniel J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antibiotic resistance; Bacterial infections; Blood and marrow transplantation

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; GENTAMICIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACTEREMIA; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NONHUMAN; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BONE MARROW TRANSPLANTATION; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871925107     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.016     Document Type: Article

References (28)

1. Frère P., Baron F., Bonnet C., et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant 2006, 37:411-418.
2. Majhail N., Weisdorf D. Complications after hematopoietic cell transplantation. Hematology: Basic Principles and Practice 2009, 1-99. Elsevier, New York, NY.
3. Busca A., Cavecchia I., Locatelli F., et al. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis 2011, Available at, Accessed: January 10, 2012. http://www.ncbi.nlm.nih.gov/pubmed/21599817.
4. Engels E.A., Ellis C.A., Supran S.E., et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 1999, 28:256-266.
5. Bodey G.P. Managing infections in the immunocompromised patient. Clin Infect Dis 2005, 40(suppl 4):S239.
6. Mitchell A.E., Derrington P., Turner P., Hunt L.P., Oakhill A., Marks D.I. Gram-negative bacteraemia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): risk factors, prophylaxis, therapy and outcome. Bone Marrow Transplant 2004, 33:303-310.
7. Poutsiaka D.D., Munson D., Price L.L., Chan G.W., Snydman D.R. Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated. Bone Marrow Transplant 2011, 46:300-307.
8. Beelen D.W., Elmaagacli A., Müller K.D., Hirche H., Schaefer U.W. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999, 93:3267-3275.
9. Guthrie K.A., Yong M., Frieze D., Corey L., Fredricks D.N. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:675-681.
10. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998, 41(suppl D):13-24.
11. Livermore D.M. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003, 36(suppl 1):S11-S23.
12. Oliveira A.L., De Souza M., Carvalho-Dias V.M., et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2007, 39:775-781.
13. Therriault B.L., Wilson J.W., Barreto J.N., Estes L.L. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc 2010, 85:711-718.
14. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
15. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
16. Ferrieri P. University of Minnesota Medical Center, Fairview, Clinical Microbiology Newsletters. 2005-2010 (Personal Communication).
17. Clinical and Laboratory Standards Institute; M07-A9: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Ninth Edition; and M100-S22: Performance Standards for Antimicrobial Susceptibility Testing; Twenty Second Informational Supplement; Available at: http://www.clsi.org/source/orders/categories.cfm?section=Microbiology1&CAT=MI.
18. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
19. Prentice R.L., Williams B.J., Peterson A.V. On the regression analysis of multivariate failure time data. Biometrika 1981, 68:373-379.
20. Frère P., Hermanne J.P., Debouge M.H., De Mol P., Fillet G., Beguin Y. Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant 2004, 33:745-749.
21. Collin B.A., Leather H.L., Wingard J.R., Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001, 33:947-953.
22. Abe R., Oda S., Sadahiro T., et al. Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia. Crit Care 2010, 14:R27.
23. Mikulska M., Del Bono V., Raiola A.M., et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009, 15:47-53.
24. Joo E.J., Kang C.I., Ha Y.E., et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist 2011, 17:305-312.
25. Slavin M.A., Grigg A.P., Schwarer A.P., et al. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 40:157-163.
26. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766.
27. Micek S.T., Welch E.C., Khan J., et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010, 54:1742-1748.
28. Garnica M., Maiolino A., Nucci M. Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res 2009, 42:289-293.